VG Life Sciences Broadens Ovarian Cancer Tests, Gets Approval to Study All Solid Tumor Treatments

Life Science Investing

VG Life Sciences (OTC Pink:VGLS) has obtained approval from the University of Texas Health Science Center San Antonio Institutional Review Board to extend the kinds of cancers being studied in its ongoing Phase 1 clinical trial.

VG Life Sciences (OTC Pink:VGLS) has obtained approval from the University of Texas Health Science Center San Antonio Institutional Review Board to extend the kinds of cancers being studied in its ongoing Phase 1 clinical trial.
As quoted in the press release:

Dr. Tyler Curiel, the lead investigator, said, “We now have approval to use sorafenib and HCQ to treat all solid tumors. I have identified candidate patients for this expanded protocol, and we are continuing screening for potential enrollment.

Click here to read the full VG Life Sciences (OTC Pink:VGLS) press release.